Comparative Pharmacology
Head-to-head clinical analysis: CEFTAROLINE FOSAMIL versus CEFTRIAXONE AND DEXTROSE IN DUPLEX CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CEFTAROLINE FOSAMIL versus CEFTRIAXONE AND DEXTROSE IN DUPLEX CONTAINER.
CEFTAROLINE FOSAMIL vs CEFTRIAXONE AND DEXTROSE IN DUPLEX CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ceftaroline fosamil is a prodrug that is converted to the active metabolite ceftaroline. Ceftaroline inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), including PBP2a in MRSA and PBP2x in Streptococcus pneumoniae, thereby preventing cross-linking of peptidoglycan.
Ceftriaxone is a third-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), thereby inhibiting peptidoglycan cross-linking. It has bactericidal activity against a broad range of gram-positive and gram-negative bacteria.
600 mg IV every 12 hours infused over 1 hour
1-2 g intravenously or intramuscularly every 24 hours. Maximum dose: 4 g daily.
None Documented
None Documented
Terminal elimination half-life is approximately 2.6 hours in patients with normal renal function. This supports twice-daily dosing in most infections.
Terminal elimination half-life is approximately 5.8-8.7 hours in adults, prolonged to 12-24 hours in elderly, and up to 30-72 hours in neonates. No dose adjustment in renal impairment alone; adjust in severe hepatic impairment.
Renal excretion of unchanged ceftaroline accounts for approximately 88% of the administered dose. Biliary/fecal elimination is minimal (<6%).
Renal (33-67% unchanged) and biliary (up to 40% as unchanged drug and microbiologically inactive metabolites); fecal elimination of unabsorbed drug is minimal. Dose adjustment required in combined renal and hepatic impairment.
Category A/B
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic